Skip to main content
. 2020 Mar 19;20:235. doi: 10.1186/s12885-020-06750-3

Fig. 2.

Fig. 2

Kaplan-Meier curves for the DFS outcomes among patients without trastuzumab (group 1). Patients in group 1 (255) were divided into two subgroups on average, low and high pre-NLR subgroup 1, according to the values of pre-NLR. Patients in low and high pre-NLR subgroup 1 showed no significant difference in DFS outcome. DFS, disease-free survival; pre-NLR, pretreatment neutrophil/lymphocyte ratio